Our 4P Plug & Play PET Phantom equalizer turns a network of PET scanners into a homogeneous source. Thanks to its innovative 68Ge system, it enables quantitative assessment with a reduced error with respect to other technologies on the market.
diXit 4P Phantom exploits a patented innovative technology that enables nuclear imaging scanner equalization, quantitative assessment and study comparison across a network of PET scanners. Receive the 4P via carrier, place it in the machine and run the qualification process with the help of our remote-assistance team. When finished, pack it and send it through (or back), without any hassle or extra cost.
Current PET phantoms are based on a 18F system that requires the intervention of dedicated local experts for the site / scanner qualification. This process is expensive, lengthy and intrinsically prone to errors.
Since different scanners give different readings, a program for clinical trial qualification (CTQ) is mandatory to guarantee a reliable and reproducible use of PET in prospective multi-centre clinical trials and in every-day clinical life.
The 68Ge phantom proved to be a reliable tool for PET scanner qualification, significantly reducing the error sources and increasing the reproducibility of PET-derived quantitative parameters.
It also proved to be superior to traditional qualitative assessment in several retrospective or mono-centric prospective reports.
The use of a 68Ge phantom allowed reducing the inter-scanner variability among different scanners by 2.5 times, from 74.0% to 20.5% in BAC and from 63.3% to 17.4% in SBR compared to using the 18F phantom. The CTQ criteria were fulfilled at first round in 100% and 28% of PET scanners with 68Ge and 18F, respectively.
Simplifies dramatically the procedure of inter-scanner calibration. Compatible with all types of scanners.
Minimize the statistical error
Versus the usual 18F phantom
Inter-scanner error variability reduced from 74.0% to 20.5% in BAC and from 63.3% to 17.4% in SBR vs 18F phantoms
Higher accuracy for future Q-PET-based clinical trials
Reduced human risk and errors. No manual procedures.